35 search results for: disease background

Diagnosis of Bullous Pemphigoid Interactive Patient Case
Dermatology
Diagnosis of Bullous Pemphigoid Interactive Patient Case
interactivity

An interactive patient case tool involving a deeper dive into assessing clinical presentation when diagnosing bullous pemphigoid (BP)

View more
Atopic and Nonatopic Comorbidities in AD and the Importance of Early Intervention
Dermatology
Atopic and Nonatopic Comorbidities in AD and the Importance of Early Intervention
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller reviews the increased risk of atopic and nonatopic comorbidities associated with atopic dermatitis and discusses the potential of early intervention to mitigate their development.

View more
Explore the Global Burden of Pediatric AD (PEDISTAD)
Dermatology
Explore the Global Burden of Pediatric AD (PEDISTAD)
interactivity

This interactive tool allows you to explore the global burden of AD in pediatric patients <12 years from the PEDISTAD Study.

View more
ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP
Rhinology
ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP
expert video

Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP

View more
Type 2 Inflammation Contributes to Itch and Fibrois in PN
Dermatology
Type 2 Inflammation Contributes to Itch and Fibrois in PN
expert video

Join Dr. Kwatra outlining the micro itch cycle involving type 2 cell polarization and cytokines that directly affect fibroblasts to cause more immune dysregulation in PN.

View more
KOL Video Interview – Dr Amy Paller
Dermatology
KOL Video Interview – Dr Amy Paller
expert video

In this exclusive video interview, Dr Amy Paller discusses two topics: 1) The importance of CCL17 (TARC) as a biomarker in pediatric patients with AD, and 2) How IL-4 and IL-13 contribute to skin barrier dysfunction in AD.

View more
Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone
Dermatology
Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone
expert video

Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation

View more
ADVENT Forum 2025 Event Page
Awareness Day
4
April
2025
Awareness Day
ADVENT Forum 2025 Event Page

From the April 2025 ADVENT Forum in Lisbon, Portugal, this event page serves to spotlight curated soundbites from dermatology and immunology experts that connect the evolving science of type 2 inflammation to clinical application.

EAPS
Congress
17
October
2024
Congress
ADVENT at EAPS 2024

The ADVENT program will present a symposium to discuss diagnosis, pathophysiology, comorbidities of atopic dermatitis in children, as well as emerging treatment options for management of atopic dermatitis (AD) in children, who are candidates for systemic therapy at the 2024 European Academy of Paediatric Societies (EAPS) Congress.

Learn more about how dysregulated type 2 inflammation contributes to polymorphous lesions and dermal epidermal splitting in bullous pemphigoid
Dermatology
Bullous Pemphigoid (BP) Pathophysiology Infographic
Infographic

A static infographic detailing how autoimmunity and Type 2 inflammation play a critical role in the pathophysiology of Bullous Pemphigoid (BP).

View more
ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?
Dermatology
ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?
Podcast

This podcast episode looks at the epidemiology, clinical presentation and classification of atopic dermatitis of the hand and feet and the impact it has on patients' quality of life.

View more